SCHEMBL25635406

SCHEMBL25635406

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(Br)c(Cl)cn1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.38
SSTR4 P31391 1/20 0.34
CNR2 P34972 1/20 0.33
STK17B O94768 1/20 0.33
STK17A Q9UEE5 1/20 0.33
BACE1 P56817 2/20 0.32
PDPK1 O15530 1/20 0.32
USP30 Q70CQ3 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31508057 0.89 SYK (0.38) SYKSSTR4STK17BSTK17ABACE1
SCHEMBL16418569 0.89 SYK (0.38) SYKSSTR4STK17BSTK17ABACE1
SCHEMBL16418854 0.87 SYK (0.39) SYKCNR2STK17BSTK17ABACE1
SCHEMBL24394307 0.85 SYK (0.37) SYKSSTR4STK17BSTK17ABACE1
SCHEMBL29567771 0.85 SYK (0.37) SYKSSTR4STK17BSTK17ABACE1
SCHEMBL24030998 0.84 USP30 (0.37) SYKSSTR4BACE1PDPK1USP30
SCHEMBL17781288 0.82 SYK (0.34) SYKSSTR4BACE1USP30CA12
SCHEMBL24035440 0.82 SYK (0.37) SYKCNR2STK17BSTK17APDPK1
SCHEMBL1180650 0.81 SYK (0.36) SYKSSTR4BACE1PDPK1USP30
SCHEMBL24288084 0.80 SYK (0.38) SYKSTK17BSTK17APDPK1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 US disclosed
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 US disclosed
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-06-22 US disclosed
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-06-22 US disclosed
EP-4141004-A1 POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192703-A1 Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof CDK9, CDK8, CDK19 SYK 1049/4885SSTR4 3157/4885CNR2 2750/4885
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof CDK9, CDK7, CDK8 SYK 499/4885SSTR4 3717/4885CNR2 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.